How Is Vasculitis Treated?

Vasculitis encompasses a diverse group of disorders characterized by inflammation and damage to blood vessel walls. Treatment is not one-size-fits-all; it depends heavily on the specific type of vasculitis, the size and location of affected vessels, disease severity, and whether vital organs—such as the kidneys, lungs, or nervous system—are involved.

For mild, localized forms—like cutaneous small-vessel vasculitis—management may involve observation alone or short-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose corticosteroids. In contrast, systemic or life-threatening vasculitides—including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA)—require aggressive immunosuppression.

First-line therapy for severe ANCA-associated vasculitides typically includes high-dose glucocorticoids combined with either cyclophosphamide or rituximab. Rituximab—an anti-CD20 monoclonal antibody—is now preferred in many cases due to its favorable safety profile and proven efficacy in inducing remission. For patients with refractory disease or those at high risk of relapse, newer agents such as avacopan (a complement C5a receptor inhibitor) have demonstrated benefit as steroid-sparing adjuncts.

Long-term management emphasizes sustained remission while minimizing treatment-related toxicity. Maintenance therapy—often with azathioprine, methotrexate, or rituximab—typically follows induction and may continue for 18–24 months or longer, guided by clinical assessment and serologic markers like ANCA titers. Close monitoring for infection, bone health, glucose metabolism, and cardiovascular risk is essential throughout the treatment course.

Ultimately, optimal outcomes depend on early diagnosis, accurate classification, multidisciplinary care—including rheumatology, nephrology, pulmonology, and pathology—and individualized therapeutic strategies tailored to each patient’s disease phenotype and comorbidities.